n INTRODUCTION
The introduction of biological therapies has significantly improved the outcome of inflammatory rheumatic diseases. As most of these diseases affect women and men in childbearing age, some concerns have been voiced as to the safety of these drugs in relation to reproduction and pregnancy. Currently, ten biological agents have been approved for rheumatic diseases. These include anti-tumor necrosis factor α (TNFα) inhibitors (etanercept, infliximab, adalimumab, golimumab and certolizumab pegol), an anti-CD20 antibody (rituximab), an IL-6 inhibitor (tocilizumab), an IL-1 receptor antagonist (anakinra), a T cell costimulation modulator (abatacept) and an anti-Blys antibody (belimumab). Albeit the efficacy and safety of these agents have been studied in both clinical trials and increasingly often in long-term observational studies, little attention in literature has been given to their use in pregnancy. According to the United States Food and Drug Administration (FDA) classification concerning the use of medications in pregnancy, anti-TNFα inhibitors and anakinra are classified in category B, while the others in category C. (1) However, this classification and the presumed safety of these drugs are based on limited data. Given primarily to the lack of controlled studies, the current manufacturers' guidelines in Italy (2) recommend that all licensed biological therapies be discontinued prior to conception for variable time intervals (Table I) . Besides registry data, some case reports and small case series (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) have been published reporting exposure to biologics and pregnancy outcomes. However, large population-based studies are limited, and there is a lack of prospective data in pregnant women. The increasing use of antibody-based therapy prompts the need SUMMARY The introduction of biological therapies has significantly improved the outcome of inflammatory rheumatic diseases. As most of these diseases affect women and men in childbearing age, some concerns have been voiced as to the safety of these drugs in relation to reproduction and pregnancy. Data from many hundreds of pregnancies in patients affected by inflammatory bowel disease and inflammatory arthritis have suggested that exposure to anti-TNF therapies at conception and/or during pregnancy is not associated with adverse pregnancy outcomes or any increase in congenital abnormalities. However, the exposure to anti-TNFα agents, particularly to monoclonal antibodies, in late pregnancy is associated with high drug levels in the newborn and their long-term effects on children remain unknown. Therefore, limiting the use of anti-TNFα to the first 30 weeks of pregnancy is recommended to reduce fetal exposure. Live-virus vaccines should be given only when levels of anti-TNFα drugs are undetectable in the serum of infants. Studies suggest that many of these drugs do enter breast milk in small amounts, but the extent to which the infant absorbs them is less clear. Limited reports have not suggested adverse pregnancy outcomes in women whose partners were exposed to anti-TNF therapies at the time of conception. Pregnancy data for rituximab, abatacept, anakinra, tocilizumab and belimumab are limited and their use in pregnancy cannot currently be recommended. for further studies in this group of patients. This review aims to summarize the current information available regarding the use of biological drugs during conception, pregnancy and breastfeeding.
n BIOLOGICAL THERAPIES IN THE PREGNANT PATIENT
The use of biological therapies is associated with an increased risk of serious and opportunistic infection (54, 55) . The survival of the foetus in the womb is subject to an altered Th1/Th2 cytokine balance with Th2 predominance and T-cell transient anergy during pregnancy, in order to ensure a maternal tolerance to paternal allo-antigens expressed by the foetus (56, 57) . Moreover, it has recently been reported that regulatory T lymphocyte cells are increased in normal pregnancy and play a critical role in embryo implantation and in the maintenance of the maternal immune tolerance to the semi-allogenic fetal antigens (58 (62) . Infliximab and adalimumab showed significant placental transfer as measured by cord blood levels at birth with a concentration ratio of the cord/mother blood ranging from 87 to 400% depending on the day when the last dose was taken (62) . Interestingly, the concentration ratio of the cord/mother blood was not different when the last drug was taken from 2 to 77 days before, whereas it was significantly lower if it was taken up to 91 days before (62) . These data suggest that the continuation of infliximab and adalimumab through the third quarter until delivery imply a higher exposure of the foetus/infant to them. Due to the amount of proteolytic (62) . Certolizumab pegol levels in mothers ranged from 1.87 to 59.57 μg/mL, while, those in the cord blood ranged from below detection level (<0.41 μg/mL) to 1.66 μg/ mL (62) . It is to be noted that levels in the cord blood were undetectable in 4 out of 12 infants; this minimal transplacental transfer is probably due to a passive diffusion, even if the mechanism is not currently understood (62) . Case reports on etanercept have also found drug levels in the newborns, although they were lower than the levels in the mother's blood stream, in fact the concentration ratio of the cord/mother blood ranged from 3.6 to 7% (5, 6) . A study of macaque monkeys treated with golimumab during pregnancy and lactation showed that foetuses were exposed to high concentrations of golimumab from the end of the second quarter, and the neonates had high levels of golimumab after birth. Golimumab was detectable in the infant serum for up to 6 months after birth (64) . Belimumab was detected in umbilical cord blood and amniotic fluid in a study on cynomolgus monkeys treated with belimumab throughout pregnancy, confirming that transplacental transfer resulted in fetal exposure (65) . Case reports on rituximab given during the second and third quarter showed cord blood levels similar to or higher than maternal levels at delivery (16) (17) (18) (19) .
REVIEW
To the best of our knowledge there are no published studies of abatacept, anakinra or tocilizumab drug levels in newborns.
n SAFETY EXPERIENCE OF BIOLOGICAL DRUGS DURING PREGNANCY
Anti-TNFα
There is now growing evidence on the use of anti-TNFα in pregnancy. Figure 1 ) (66). These investigations found that, in most of cases, the exposure at conception or during pregnancy, including the second and third trimesters, was not associated with an increase in the risk of adverse neonatal outcome or congenital malformations compared with the general population. It should be noted that major congenital malformations have been reported less than in the general population, additionally no specific pattern of birth defects was identified (67). Carter et al. described a case of an association of vertebrae abnormalities, anal abnormalities, tracheal problems, esophageal problems, radius or renal defects (VATER) without renal or limb abnormalities in an infant exposed to etanercept in utero (8) . A review of the FDA safety database reported 61 types of congenital abnormalities in 41 children born to 40 mothers taking a TNFα antagonist (68) . Specifically, 24 (59%) of those children had one or more congenital abnormalities that are part of a spectrum including vertebral defects, anal atresia, cardiac defects, trachea-esophageal fistula, renal abnormalities, and limb abnormalities (VACTERL), thus raising concerns of a possible causative effect of the anti-TNFα agents. However, due to the nature of voluntary reporting to FDA, the denominator of pregnant mothers treated with anti-TNFα is not known and therefore it is not clear if the rate of occurrence is higher than expected. Moreover, because the most common abnormality reported was a cardiac defect (one of the most common abnormalities in the general population), the association is only speculative. The PIANO registry, a prospective registry of pregnant women with IBD (326 unexposed, 204 exposed to thiopurine, 291 exposed to anti-TNFα agents and 75 exposed to a combination of anti-TNFα agents and thiopurine) did not find an increase in congenital abnormalities associated with drug exposure (69) . In addition, the use of a combination therapy was not associated with an increase in any complication (spontaneous abortion, preterm birth, intrauterine growth restriction, caesarean section, or admission to neonatal intensive care unit), even when adjusted for the type or the activity of the disease. It should be noted that, at 12 months of age, infants exposed to a combination therapy with any thiopurine drugs plus either infliximab or adalimumab had a significant increase in infections compared with infants exposed to monotherapy, however the same did not occur in infants exposed to a certolizumab pegol combination therapy, thus suggesting a role of anti-TNFα that cross the placenta in the development of the immune system. A study of macaque monkeys treated with golimumab during pregnancy and lactation did not report any differences in the development or maturation of the immune system compared with standard saline injections (64) . Because infants may have therapeutic levels of anti-TNFα for several months from birth, response to vaccines is also a concern.
There is a case report of an infant exposed in utero to infliximab who received the bacillus Calmette-Guèrin (BCG) vaccine at 3 months of age (9). This infant became ill and, due to disseminated BCG, died at 4.5 months of age. This case emphasized the importance of deferring live vaccines in infants after 6 months of age when exposed to anti-TNFα in utero. On the other hand, infants exposed to infliximab in utero had an appropriate response to standard vaccinations (70) . In this respect the London Position Statement of the World Congress of Gastroenterology on the Biological Therapy for IBD stated that vaccination of infants exposed to biological therapy in utero should be given according standard schedules, except for live-virus vaccines, which are not recommended if biological agents are detectable in the infant bloodstream (71). Table III summaries the reports of maternal exposure to rituximab either prior to or during pregnancy (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) . Rituximab has various indications. The majority of patients receive the drug for non-rheumatic conditions, including severe hematologic disorders. In the literature the cases of exposure to Rituximab range from 22 months prior conception in a patient with systemic lupus erythematosus (SLE) (20) to the third quarter in a patient with idiopathic thrombocytopenic purpura (18) . Two case series have shown that the use of rituximab before pregnancy, or even close to conception, is not associated with adverse effects in the child (20, 21) . The rituximab global drug safety database reported 153 pregnancies with known outcomes (72) . These mothers were treated with rituximab and often a concomitant therapy for malignancies or various types of autoimmune diseases with an exposure to this drug ranging from 7 weeks of gestation until the third quarter. These data showed an increased rate of spontaneous abortion (22%) and prematurity (24%). Moreover, in full-term pregnancies neonatal deaths or congenital malformations (2.2%) were not higher than in the general population. Hematological abnormalities at birth including neutropenia and B cell depletion have been reported in 12% of the neonates; most of these abnormalities were SLE, systemic lupus erythematosus; RA, rheumatoid arthritis; TTP, thrombotic thrombocytopenic purpura; AIHA, autoimmune haemolytic anaemia; GPA, granulomatosis with polyangiitis; NHL, non-Hodgkin lymphomas; ITP, idiopathic thrombocytopenic purpura; PAN, polyrteritis nodosa; MPA, microscopic polyangiitis; T1, first trimester; T2, second trimester; T3, third trimester; SA, spontaneous abortion; SB, stillbirth; PTB, preterm birth (< 37 wk gestation); SGA, small for gestational age; wk, week; mo, month. The response to vaccination was studied in cynomolgus monkeys (73) . The offspring showed a normal ability to induce T celldependent antibody responses, following vaccination or after antigenic challenge (73, 74) . Moreover, normal vaccination response to routine childhood vaccines has been observed in several 8-20 month old children exposed to rituximab in utero (16, 17, 22) .
Rituximab

Anakinra, abatacept, tocilizumab and belimumab
Published experience on pregnancy and exposure to anakinra, abatacept, tocilizumab and belimumab is extremely limited (Table  IV) (25, 35, 36, 52, 53, 75) . Anakinra was administered throughout pregnancy to three patients with adult-onset Still's disease and the children born at term were healthy (35, 36) . First quarter exposure to abatacept in combination with methotrexate (MTX) was reported in a 33-year-old woman with rheumatoid arthritis (RA); she delivered a healthy infant who was performing well at the age of 3.5 years (25).
Embryonic and fetal developmental toxicity of tocilizumab was studied in animals without evidence of a teratogenic/dysmorphogenic effect regardless of the dose (74 
Biological therapies and breastfeeding
Information on the use of biological therapy during breastfeeding is limited to an- ti-TNFα therapies. Case reports and case series show that detectable levels of anti-TNFα in breast milk during breastfeeding was significantly lower than in the maternal bloodstream (4-6, 10, 11, 62, 76) . Drug levels in the newborn gradually decreased until they became undetectable despite breastfeeding. To date, in the few case reports of women receiving anti-TNFα therapies (primarily etanercept and infliximab) who breastfed, no adverse effects have been reported in the infants (4-6, 10, 76).
Biological therapies and fathers
The experience in men exposed to biological drugs at the time of conception is limited to anti-TNFα therapies. The first two case series suggested semen abnormalities in men exposed to infliximab (77, 78) . One of these reported asthenozoospermia in two of four men with ankylosing spondylitis receiving infliximab (77) . The other study regarding 10 men with Crohn's disease reported a significant increase in semen volume with a trend towards decreased sperm motility and normal forms after infliximab infusion (78) . However, another study on 25 men with spondyloarthritis (SpA), including 15 patients receiving anti-TNFα therapies (infliximab, adalimumab or etanercept), found no differences in sperm quality between anti-TNFα-treated patients and healthy controls. Interestingly, patients with SpA who did not receive anti-TNFα were more likely to have poor motility compared with those on treatment (79). This findings have been recently confirmed by a prospective case-control study on 10 patients with SpA treated with adalimumab showing that the anti-TNFα therapy is safe on testicular function and fertility; in addition the authors suggest that discontinuation of treatment before conception is probably unnecessary (80) . Published clinical experience on pregnancy outcome after paternal exposure to biological drugs remains limited. A total of 25 pregnancies involving 20 men resulted in 23 healthy babies, 1 miscarriage and 1 therapeutic first quarter termination following the development of hydrocephaly in the fetus (it should be noted that the father was also receiving MTX for psoriasic arthritis at the time of conception) (81, 82) . The UCB Pharma global safety database reports 24 pregnancies from fathers exposed to certolizumab pegol, which resulted into 13 live births, 4 miscarriages, 1 termination and an 6 unknown outcomes. 51 Data on paternal exposure to other biological therapies are limited. The rituximab global drug safety database reports 8 cases of men exposed to rituximab at the time of conception. Outcomes included 7 healthy term infants and 1 spontaneous miscarriage (72) .
n CONCLUSIONS
The differences in transplacental passage of biological drugs depend on their molecular structure. In fact it is greater for monoclonal antibodies and more limited for fusion proteins or F'ab fragments. On the whole, the data regarding maternal exposure to anti-TNFα at conception and/or during pregnancy do not show a worse outcome with respect to the general population. Moreover, they do not show an increase in congenital abnormalities and seem to be compatible with breastfeeding. Exposure to anti-TNFα agents in late pregnancies, particularly to monoclonal antibodies, is associated with high drug levels in the newborn, however the long-term effects on the child remain unknown. Therefore, in the clinical practice we suggest that the anti-TNF-α therapy be continued through conception and during pregnancy until the first 30 weeks of gestation, when there is a moderate-high activity of the disease. Livevirus vaccines should be given only when levels of anti-TNFα drugs are undetectable in the serum of infants. Pregnancy data for non anti-TNFα biologics are lacking and their use in pregnancy cannot be currently recommended. 
